Infliximab for hidradenitis suppurativa

British Journal of Dermatology

Volumn 149, Issue 5, 2003, Pages 1046-1049

  Sullivan, T P ^a   Welsh, E ^a   Kerdel, F A ^a   Burdick, A E ^a   Kirsner, R S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Hidradenitis suppurativa; Infliximab; Tumour necrosis factor

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; HISTOPLASMOSIS; HUMAN; HYPOTENSION; LUNG ASPERGILLOSIS; MALE; MORBIDITY; NECROTIZING FASCIITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SUPPURATIVE HIDRADENITIS; TREATMENT OUTCOME; TUBERCULOSIS; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0347382296     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2003.05663.x     Document Type: Review

References (16)

1. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-7.
2. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001; 137: 1571-4.
3. Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab. a chimeric human/mouse anti-TNFalpha antibody. Bone Marrow Transplant 2001; 28: 47-9.
4. Roy MK, Appleton MA, Delicata RJ et al. Probable association between hidradenitis suppurativa and Crohn's disease: significance of epithelioid granuloma. Br J Surg 1997; 84: 375-6.
5. Ostlere LS, Langtry JA, Mortimer PS, Staughton RC. Hidradenitis suppurativa in Crohn's disease. Br J Dermatol 1991; 125: 384-6.
6. Tsianos EV, Dalekos GN, Tzermias C et al. Hidradenitis suppurativa in Crohn's disease. A further support to this association. J Clin Gastroenterol 1995; 20: 151-3.
7. Mouser JF, Hyams JS. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther 1999; 21: 932-42.
8. Old LJ. Tumor necrosis factor (TNF). Sci Am 1988; 258: 59-60.
9. Radema SA, Dulleman H, Mevissen M et al. Anti-TNFα therapy decreases the production of chemokines in patients with Crohn's disease. In: Cytokine Production, Immune Activation, and Neutrophil Migration in Inflammatory Bowel Disease [Dissertation] Amsterdam, Netherlands: University of Amsterdam, 1996.
10. Elliot MJ, Maini RN, Feldman M et al. Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
11. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
12. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099-100.
13. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78: 47-8.
14. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2001; 112: 78-9.
15. Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy - a critical review. Can J Gastroenterol 2001; 15: 376-84.
16. Charles PJ, Smeenk RJ, De Jong J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.